Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; first stage of multi-phase MotifAi Assistant deployment focuses on study delivery operations
BOSTON and LONDON, Jan. 29, 2026 /PRNewswire-PRWeb/ -- uMotif – one of the clinical trial technology market's fastest growing companies – increased year-over-year bookings in 2025 as it expanded its customer base, increased contract value, and continued to demonstrate market leadership in how clinical trial patient data are collected.
uMotif's portfolio is anchored by modern, patient-first eCOA/ePRO, and enhanced by solutions for consent management, trial awareness, patient transport, and site productivity.
uMotif 2025 achievements included…
Major eCOA Market Contender Status – uMotif achieved Major Contender status in its inaugural participation in the Everest Group Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment. uMotif earned the highest possible score for technology capability and recognition for excellent support services, characterizing uMotif as proactive and willing to listen to client needs to deliver high-quality solutions, and validating uMotif's long-standing patient-centric approach to technology design, driving high compliance and quality data capture in clinical trials. Learn more here
Leveraging AI to Improve Study Delivery Operations – uMotif announced the launch of MotifAi Assistant, an AI-driven, multi-phase automation initiative across its product portfolio to help its study teams enhance accuracy, accelerate timelines, and improve data quality for sponsors and CROs. The first phase of the MotifAi Assistant initiative focuses on study delivery operations, directly benefitting customers by enabling faster study builds, improved documentation quality, and even greater consistency across all projects. Read more here
Guided Publication of Best Practices for Event-Driven eDiaries (EDeDs) – On behalf of the Critical Path Institute (C-Path), Chief Scientific Officer Florence Mowlem PhD led the publication of the first fundamental project to define best practices for EDeD design and implementation in a decade. Dr. Mowlem's co-authors represented uMotif, Lilly; Suvoda; UCB; AstraZeneca; AbbVie; Clario; Medidata; Parexel International; FDA; GSK; Otsuka; Novartis; Signant Health; Critical Path Institute; IQVIA; and, Medrio. Read the article in Nature Digital Medicine
uMotif CEO Steve Rosenberg said, "uMotif continues to achieve strong and steady growth and influence in a crowded market because we offer innovative technology that works as promised, our team is proactive and adaptive, and our breadth and depth of expertise uniquely qualify us to make major contributions to the clinical trial ecosystem so sponsors can run faster, smarter trials."
uMotif will sponsor, exhibit and speak at the following industry events. Arrange an executive meeting at umotif.com
- SCOPE Summit for Clinical Op Executives, February 2-5
- 18th Annual Outsourcing in Clinical Trials West Coast, February 11-12
- Clinical Outsourcing Group UK, March 3-4
- acdm26, March 15-17
- Clinical Outsourcing Group Nordics, March 24-25
About uMotif
Putting patients first is in uMotif's DNA. The modern uMotif eCOA platform delivers faster, high-quality clinical trials and real-world studies by putting patients at the core of research. Combined with uMotif's robust site tools – including consent management, site productivity, and trial awareness – the platform strengthens the patient-site relationship, which is key to improving eCOA compliance and retention. With cloud hosting in the US, Europe, and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports all study phases and indications. Visit www.umotif.com
Media Contact
Brenda Nashawaty, uMotif Ltd, 1 6176883253, [email protected], www.umotif.com
Elaine Maynard, uMotif, 1 6176883253, [email protected], www.umotif.com
SOURCE uMotif Ltd
Share this article